Clinical trials
Progression, Disease clinical trials
Below are recruiting progression, disease clinical trials, each written for real people, not researchers. We’re tracking 207 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06267781Recruiting
MS progression and immune cells after bone marrow transplant and other therapies
This study looks at how well different treatments, including bone marrow transplant, alemtuzumab, ocrelizumab, and ofatumumab, work for people with relapsing-remitting MS who have active disease. It will help doctors understand which therapy might slow disease progression best.
MilanAges 18 years+ - NCT06083363Recruiting
Recovery after severe lung infection
This study follows patients who had severe pneumonia or acute respiratory distress syndrome (ARDS) in the intensive care unit (ICU) to understand how they recover over time. It aims to identify factors that affect recovery trajectories.
Tortosa, TarragonaAges 18 years+ - NCT06378892RecruitingPhase 2
Study of chemo plus lorlatinib for ALK+ lung cancer
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
AvianoAges 18 years+ - NCT06501950Recruiting
Measuring silent MS progression with advanced tests
This study is looking for people with MS who are already on a monoclonal antibody therapy. It aims to measure subtle signs of disease progression using advanced tests, even if you feel stable.
Düsseldorf, North Rhine-WestphaliaAges 18 years+ - NCT06200311Recruiting
Atrial fibrillation ablation to prevent heart damage in women and men
This trial tests whether a procedure called AF ablation (which treats irregular heartbeats) can stop further damage to the heart muscle caused by atrial fibrillation. It may help people with both atrial fibrillation and early signs of heart muscle weakening.
GroningenAges 65–80 - NCT07651540Recruiting
Understanding Sensory Nerve Damage: The Neuronoscore Study
This study helps doctors better understand and measure sensory nerve damage (nerves that feel pain, temperature, and touch). You may qualify if you have a specific type of nerve damage caused by cancer, autoimmune disease, platinum chemotherapy, or a rare genetic condition.
AngersAges 18 years+ - NCT07560865RecruitingPhase 1
New Cell Therapy for Recurring Brain Cancer
This study tests FT536, a new cell-based treatment, for people with a specific type of brain cancer (WHO Grade 4 astrocytoma) that has come back after standard treatment. The trial combines the new therapy with surgery to see if it can help stop the cancer from growing further.
Minneapolis, MinnesotaAges 18–75 - NCT06209606RecruitingEarly Phase 1
Blood test study for multiple myeloma progression
This study is testing whether a blood test that measures a protein called BCMA can help doctors know if your multiple myeloma is getting worse. You may be able to join if your myeloma has come back or not responded to at least two prior treatments, and you have not taken the drug Ruxolitinib before.
West Hollywood, CaliforniaAges 18 years+ - NCT07556042Recruiting
Machine Learning to Predict Scoliosis Progression in Teens
This study uses artificial intelligence to predict how adolescent scoliosis (curvature of the spine) might progress over time. By understanding which teens are most at risk, doctors hope to catch and treat the condition earlier.
IstanbulAges 10–18 - NCT06760923Recruiting
Urine test for ovarian cancer detection and tracking
This study looks at proteins in urine to help find ovarian cancer earlier and track how the disease changes. It aims to provide a non-invasive way to tell the difference between benign and malignant pelvic masses.
Changsha, HunanAges 18 years+ - NCT06278428Recruiting
Epilepsy in Infants: Genes and Disease Course
This study looks at children with severe epilepsy that starts before age 2. It aims to understand how different gene changes affect the disease and how it progresses over time.
Ho Chi Minh CityAges Up to 1.9 years - NCT04606732Recruiting
Tracking heart risk changes after COVID-19 hospitalization
This study looks at how COVID-19 affects heart health over time in people who were hospitalized. Your results may help doctors predict prognosis and understand who is at higher heart risk after recovery.
BolognaAges 18 years+ - NCT06943326Recruiting
How food given through a tube affects recovery in sepsis patients
This trial tests if the type of tube feeding given to sepsis patients in the ICU can affect their recovery. It aims to find the best diet to help fight the infection and prevent complications.
SanliurfaAges 18 years+ - NCT07106762RecruitingPhase 2/Phase 3
Study of new targeted drug vs chemo for bladder cancer
This trial tests a new drug called Izalontamab Brengitecan (a targeted therapy that delivers chemo straight to cancer cells) against standard platinum chemotherapy for people whose bladder cancer worsened after immunotherapy. It may be an option if you are fit for chemo but haven't had platinum chemo recently.
Gilbert, ArizonaAges 18 years+ - NCT07112066Recruiting
Heart imaging study for ATTR amyloidosis patients
This study uses heart imaging to track disease progression in people with ATTR cardiac amyloidosis who are about to start tafamidis treatment. It aims to understand how the disease changes over time.
Zurich, Canton of ZurichAges Any age - NCT06351670Recruiting
Monitoring early to moderate age-related macular degeneration with AI
This study uses artificial intelligence to track changes in the eyes of people with early or intermediate age-related macular degeneration (AMD). It aims to better understand how the disease progresses and may help doctors personalize care.
ViennaAges 55–99 - NCT06351657Recruiting
Monitoring macular degeneration with AI to detect progression
This trial uses artificial intelligence to track changes in the eyes of people with advanced age-related macular degeneration (AMD) that has caused a specific type of damage (atrophy) in the retina. The goal is to see if AI can help detect when the disease gets worse, so doctors can personalize monitoring for each patient.
ViennaAges 55–99 - NCT06922994RecruitingPhase 2
Testing atorvastatin for arrhythmogenic cardiomyopathy
This trial tests if a common cholesterol medicine, atorvastatin, can slow the progression of arrhythmogenic cardiomyopathy, a genetic heart condition that can cause abnormal heart rhythms. If you have this condition, joining this study may help researchers find a new way to protect your heart.
Pavia, PVAges 18 years+ - NCT06844643Recruiting
Axial spondyloarthritis progression study in China
This study tracks how axial spondyloarthritis progresses over time in Chinese patients. It helps doctors understand the natural course of the disease and improve care.
BeijingAges 18 years+ - NCT06780670RecruitingPhase 2/Phase 3
Comparing a new treatment to standard care for advanced prostate cancer
This study tests a new drug (AAA817) against the usual treatments for men with advanced prostate cancer that has stopped responding to a type of targeted radiation therapy (Lu-PSMA). The goal is to see if the new drug can slow the cancer's growth better than standard options.
Scottsdale, ArizonaAges 18–100 - NCT06652048RecruitingPhase 2
High-dose Furmonertinib for advanced lung cancer after progression
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06344000Recruiting
Nutrition and disease progression in bronchiectasis
This study looks at how nutrition affects the course of bronchiectasis, a lung condition that causes coughing and frequent infections. It may help find ways to slow the disease down.
Wuhan, HubeiAges 18–100 - NCT05783804Recruiting
Early cholesterol-lowering to help reverse artery plaque
This trial studies whether starting strong cholesterol-lowering treatment early can reduce or reverse plaque in the arteries. It may help protect the heart over time, especially for people with inherited high cholesterol.
Amsterdam, North HollandAges 18–50 - NCT06079567Recruiting
Study of FSHD2 progression over 18 months
This study follows people with FSHD2 over 18 months to learn how the disease progresses and affects daily life. No new drugs are tested—just regular check-ups and an MRI scan.
LeuvenAges 18–75
Hear when a new Progression, Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for progression, disease?
- Yes. Clin2 currently lists 207 recruiting progression, disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a progression, disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a progression, disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.